Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies

For the purpose of exploring the development, pharmacology and clinical trial program related to dulaglutide, we conducted a nonsystematic review of dulaglutide, focusing on the AWARD (Assessment of Weekly Administration of LY2189265 [dulaglutide] in Diabetes Assessment) program of randomized, phase...

Full description

Bibliographic Details

Published in:	Сахарный диабет
Main Authors:	Marina V. Shestakova, Ekaterina A. Yudovich
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2017-08-01
Subjects:	diabetes mellitus type 2, dulaglutide, glucagon-like peptide 1, hypoglycemic agents
Online Access:	https://www.dia-endojournals.ru/jour/article/view/8347